Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders.
China Hinye Pharmaceutical Co. Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, dyspepsia, reflux esophagitis, Barrett esophagus, Helicobacter pylori infection and gastric cancer.
Abstract ideas are not generally eligible for patents in the U.S., but a recent dispute heard by the U.S. Patent Trial and Appeal Board adds a new twist to the question.
Aurigene Oncology Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety via a linker acting as SMARCA2 and/or SMARCA4 degradation inducers reported to be useful for the treatment of cancer.
Youngene Therapeutics Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, metabolic syndrome, stroke, metabolic dysfunction-associated steatohepatitis, cardiovascular and renal disorders, among others.
Guangzhou Henovcom Bioscience Co. Ltd. has synthesized prodrugs of rotigotine reported to be useful for the treatment of restless legs syndrome, depression and Parkinson’s disease.
Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
RSS
